

# Simona Ferraro

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4821437/simona-ferraro-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49  
papers

594  
citations

13  
h-index

22  
g-index

52  
ext. papers

755  
ext. citations

5  
avg, IF

4.29  
L-index

#	Paper	IF	Citations
49	Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality.. <i>BJU International</i> , <b>2022</b> , 129, 418	5.6	1
48	Reply to: Spurious results for total and free prostate-specific antigen (PSA); sometimes really "a riddle wrapped in a mystery inside an enigma".. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2022</b> ,	5.9	
47	Managing folate deficiency implies filling the gap between laboratory and clinical assessment.. <i>Clinical Nutrition</i> , <b>2021</b> , 41, 374-383	5.9	2
46	Is pre-biopsy serum prostate specific antigen retesting always justified? A study of the influence of individual and analytical factors on decision making for biopsy referral. <i>Clinica Chimica Acta</i> , <b>2021</b> , 516, 77-82	6.2	2
45	Definition of Outcome-Based Prostate-Specific Antigen (PSA) Thresholds for Advanced Prostate Cancer Risk Prediction. <i>Cancers</i> , <b>2021</b> , 13,	6.6	11
44	Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 543-553	5.5	15
43	Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 602-609	5.5	8
42	Benefit-harm ratio of the diagnostic workup in patients with prostate cancer of Gleason score from 9 to 10. <i>Cancer</i> , <b>2021</b> , 127, 4310-4311	6.4	
41	Measurement of Serum Neuron-Specific Enolase in Neuroblastoma: Is There a Clinical Role?. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 667-675	5.5	9
40	Trueness evaluation and verification of inter-assay agreement of serum folate measuring systems. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, 1697-1705	5.9	3
39	More robust analytical evidence should support the selection of human chorionic gonadotropin assays for oncology application. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, e61-e63	5.9	1
38	Human chorionic gonadotropin in oncology: a matter of tight (bio)marking. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, e57-e60	5.9	2
37	Definition of analytical quality specifications for serum total folate measurements using a simulation outcome-based model. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, e66-e68	5.9	5
36	A step forward in identifying the right human chorionic gonadotropin assay for testicular cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, 357-360	5.9	4
35	Reflex Testing of Free Prostate-Specific Antigen as Effective Health Care Policy. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2019</b> , 143, 1045	5	2
34	Defining the plasma folate concentration for optimal neural tube defects prevention cannot ignore the impact of the employed methodology. <i>American Journal of Clinical Nutrition</i> , <b>2019</b> , 110, 780-781	7	4
33	Making new biomarkers a reality: the case of serum human epididymis protein 4. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2019</b> , 57, 1284-1294	5.9	14

32	Human Chorionic Gonadotropin Assays for Testicular Tumors: Closing the Gap between Clinical and Laboratory Practice. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 270-278	5.5	16
31	Serum human epididymis protein 4 vs. carbohydrate antigen 125 in ovarian cancer follow-up. <i>Clinical Biochemistry</i> , <b>2018</b> , 60, 84-90	3.5	10
30	Reply to: Hyperuricemia does not seem to be an independent risk factor for coronary heart disease. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2018</b> , 56, e63-e64	5.9	1
29	The role of laboratory in ensuring appropriate test requests. <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 555-561	3.5	28
28	Estimation of the reference interval for serum folate measured with assays traceable to the WHO International Standard. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2017</b> , 55, e195-e196	5.9	7
27	Tackling serum folate test in European countries within the health technology assessment paradigm: request appropriateness, assays and health outcomes. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2017</b> , 55, 1262-1275	5.9	10
26	Cystatin C provides a better estimate of the effect of glomerular filtration rate on serum human epididymis protein 4 concentrations. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, 1629-34	5.9	6
25	Laboratory medicine in the new healthcare environment. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, 523-33	5.9	35
24	Verification of the harmonization of human epididymis protein 4 assays. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, 1635-43	5.9	13
23	Reference intervals for the Kryptor second-generation chromogranin A assay. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2016</b> , 54, e335-e337	5.9	3
22	Laboratory medicine as the science that underpins medicine: the "high-sensitivity" troponin paradigm. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2015</b> , 53, 653-64	5.9	11
21	A new robust statistical model for interpretation of differences in serial test results from an individual. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2015</b> , 53, 815-22	5.9	8
20	Tumor Marker Ordering: Do Not Lose Control: A Prospective Clinical Trial. <i>American Journal of Clinical Pathology</i> , <b>2015</b> , 144, 649-58	1.9	12
19	Human epididymis protein 4: factors of variation. <i>Clinica Chimica Acta</i> , <b>2015</b> , 438, 171-7	6.2	31
18	Body mass index does not influence human epididymis protein 4 concentrations in serum. <i>Clinica Chimica Acta</i> , <b>2015</b> , 446, 163-4	6.2	8
17	Troponin T measured with highly sensitive assay (hsTnT) on admission does not reflect infarct size in ST-elevation myocardial infarction patients receiving primary percutaneous coronary intervention. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2015</b> , 53, e173-4	5.9	0
16	Tracing a roadmap for vitamin B12 testing using the health technology assessment approach. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2014</b> , 52, 767-77	5.9	4
15	Is serum human epididymis protein 4 ready for prime time?. <i>Annals of Clinical Biochemistry</i> , <b>2014</b> , 51, 128-36	2.2	13

14	The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2014</b> , 52, 1625-31	5.9	19
13	Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. <i>Clinical Biochemistry</i> , <b>2013</b> , 46, 148-51	3.5	35
12	Estimate of intraindividual variability of C-reactive protein: a challenging issue. <i>Clinica Chimica Acta</i> , <b>2013</b> , 419, 85-6	6.2	7
11	Multi-marker network in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: when and what to measure. <i>Clinica Chimica Acta</i> , <b>2013</b> , 417, 1-7	6.2	2
10	New insights in the pathophysiology of acute myocardial infarction detectable by a contemporary troponin assay. <i>Clinical Biochemistry</i> , <b>2013</b> , 46, 999-1006	3.5	5
9	Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. <i>Journal of Clinical Pathology</i> , <b>2013</b> , 66, 273-81	3.9	112
8	Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood. <i>Clinica Chimica Acta</i> , <b>2012</b> , 413, 888-93	6.2	13
7	The prognostic value of plasma fibrinogen concentrations of patients with ST-elevation myocardial infarction and treated by primary percutaneous coronary intervention: a cautionary message. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2012</b> , 72, 355-62	2	3
6	Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2012</b> , 50, 243-53	5.9	23
5	Reevaluating serum ferritin as a marker of body iron stores in the traceability era. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2012</b> , 50, 1911-6	5.9	31
4	Prognostic value of cystatin C in acute coronary syndromes: enhancer of atherosclerosis and promising therapeutic target. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2011</b> , 49, 1397-404	5.9	25
3	From multimarker approach to multiplex assays in acute coronary syndromes: what are we searching for?. <i>Acute Cardiac Care</i> , <b>2010</b> , 12, 18-24		1
2	Impact of calibration fitting models on the clinical value of chromogranin A. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2009</b> , 47, 1297-303	5.9	1
1	Different patterns of NT-proBNP secretion in acute coronary syndromes. <i>Clinica Chimica Acta</i> , <b>2009</b> , 402, 176-81	6.2	4